CoChat

COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease

Willoughby, Derek A, Moore, Adrian R, Colville-Nash, Paul R · 2000 · The Lancet

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

A new generation of non-steroidal anti-inflammatory drugs has been described that selectively targets the inducible isoform of cyclo-oxygenase, cyclo-oxygenase 2 (COX-2). This isoform is expressed at sites of inflammation, which has led to the speculation that its inhibition could provide all the benefits of current nonsteroidal anti-inflammatory drugs, but without their major side-effects on the gastrointestinal system (which are due to inhibition of COX-1). We have shown that COX-2 (identified by use of specific antibodies) is induced during the resolution of an inflammatory response, inhibition of COX-2 resulting in persistence of the inflammation due to the prevention of the synthesis of a range of anti-inflammatory prostanoids. We propose that there is a third isoform of this enzyme family, COX-3, a proposal that will have implication for the prescription of both existing and new generation anti-inflammatory drugs, and might represent a new therapeutic target.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(99)12031-2

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 19 references

Cited by

See all 356

Metadata

Authors
Willoughby, D. A., Moore, A. R., & Colville-Nash, P. R.
Affiliations
St Bartholomew's Hospital (GB)
Corresponding author
Willoughby, Derek A
Venue
The Lancet
Publisher
Elsevier BV
Published
2000-02
Volume
355
Issue
9204
Pages
646-648
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2120102288
Cited by
298
References
19
Citations by year
2026: 3 · 2025: 3 · 2024: 6 · 2023: 7 · 2022: 11 · 2021: 13 · 2020: 11 · 2019: 11 · 2018: 7 · 2017: 9 · 2016: 7 · 2015: 6 · 2014: 12 · 2013: 6 · 2012: 15
FWCI
15.10
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
Keywords
cyclooxygenase-2, cyclooxygenase-1, COX-2 selective inhibitors, nonsteroidal anti-inflammatory drugs, chronic inflammatory diseases, prostanoids, gastrointestinal adverse effects, inflammation resolution, anti-inflammatory drug targets
MeSH terms
Animals, Anti-Inflammatory Agents, Non-Steroidal, Humans, Inflammation, Isoenzymes, Membrane Proteins, Peroxidases, Prostaglandin-Endoperoxide Synthases, Cyclooxygenase Inhibitors, Protein Isoforms, Cyclooxygenase 2, Cyclooxygenase 2 Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease. https://app.cochat.ai/papers/10.1016/s0140-6736(99)12031-2
The paper
Willoughby, D. A., Moore, A. R., & Colville-Nash, P. R. (2000). COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease. The Lancet. https://doi.org/10.1016/s0140-6736(99)12031-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.